Delivery Order SPE2DB25D3110-SPE2DB25FTEDR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,358.35 to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion pharmaceutical supply vehicle that runs through December 2026. The delivery order is scheduled for completion by July 28, 2025, with performance...
- The Defense Logistics Agency (DLA) awarded a $10,638.89 delivery order to AmerisourceBergen Drug Corp for VAXNEUVANCE 0.5 ML syringes on July 29, 2025, with completion targeted for July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. The delivery order represents pharmaceutical procurement to support federal medical supply...
- The Defense Logistics Agency awarded a $6,121.40 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vaxneuvance 0.5 ML syringes. This competitive, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
- The Defense Logistics Agency awarded a $17,804.46 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Vaxneuvance 0.5 mL syringes. This is a firm fixed price, competitively awarded contract with an ultimate completion date of July 22, 2025, and will be performed in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 ML syringes, with a contract ceiling value of $2,740.78. The award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the contract was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of...
- The Defense Logistics Agency awarded a delivery order valued at $2,740.70 to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes on August 19, 2025, with an ultimate completion date of August 20, 2025. This contract utilized firm fixed price pricing and was competitively awarded without any set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $58,226.32 to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes. This firm fixed-price contract, issued on July 31, 2025, represents a non-set-aside award made through open competition. The work will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 mL syringes, with a ceiling value of $3,893.84. The contract, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $13,360.62 to AmerisourceBergen Drug Corp for Vaxneuvance 0.5 mL syringes on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of VAXNEUVANCE 0.5 ML syringes valued at $20,438.65 with a firm fixed price contract type. This order is expected to be completed by July 21, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award was made through a competitive process with no set-aside designation, reflecting AmerisourceBergen's proven capability to meet federal...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEDRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,345.59 to AmerisourceBergen Drug Corp for the supply of Vaxneuvance 0.5 ML syringes. This competitively awarded, firm fixed-price delivery order was issued on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's comprehensive DLA IDC vehicle enables it to supply an extensive range of pharmaceutical products and medical supplies, including specialty medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems. As a non-set-aside award, this delivery order demonstrates the company's capability to meet federal requirements through open competition and represents routine pharmaceutical resupply operations under its broader pharmaceutical support contract with the DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/21/25 |